Y-mAbs Therapeutics

OverviewSuggest Edit

Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. The Company applies its antibody capabilities to create immunotherapies for cancer patients of all ages. Y-mAbs Therapeutics' mission is to develop better and safer antibody based pediatric oncology products addressing clear unmet medical needs.

TypePublic
Founded2014
HQNew York, US
Websiteymabs.com

Latest Updates

Employees (est.) (Dec 2018)32(+40%)
Share Price (Jul 2020)$35.1 (-1%)
Cybersecurity ratingAMore

Key People/Management at Y-mAbs Therapeutics

Thomas Gad

Thomas Gad

Chairman

Y-mAbs Therapeutics Office Locations

Y-mAbs Therapeutics has offices in New York, Nutley and Hørsholm
New York, US (HQ)
230 Park Ave #3350
Nutley, US
111 Ideation Way basement floor, room c
Nutley, US
340 Kingsland St building 102
Hørsholm, DK
Agern Alle 11
Show all (4)

Y-mAbs Therapeutics Financials and Metrics

Y-mAbs Therapeutics Revenue

USD

Net income (Q1, 2020)

(26.2m)

EBIT (Q1, 2020)

(26.7m)

Market capitalization (31-Jul-2020)

1.4b

Closing stock price (31-Jul-2020)

35.1

Cash (31-Mar-2020)

185.8m

EV

1.2b
Y-mAbs Therapeutics's current market capitalization is $1.4 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

3.2m4.9m9.0m19.5m

R&D expense

13.9m14.3m34.3m63.5m

Operating expense total

17.0m19.2m43.2m83.0m

EBIT

(17.0m)(19.2m)(43.2m)(83.0m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

766.0k2.7m3.7m4.1m4.7m8.1m

R&D expense

3.1m8.7m12.5m14.5m19.7m18.6m

Operating expense total

3.8m11.4m16.3m18.6m24.4m26.7m

EBIT

(3.8m)(11.4m)(16.3m)(18.6m)(24.4m)(26.7m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

16.9m90.5m147.8m207.1m

Prepaid Expenses

3.7m

Current Assets

17.3m91.4m151.5m212.0m

PP&E

205.0k2.1m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

70.2m163.3m134.2m120.2m98.2m185.8m

Prepaid Expenses

2.8m3.0m1.4m

Current Assets

71.7m166.0m137.0m123.2m99.6m189.8m

PP&E

118.0k162.0k400.0k390.0k1.7m2.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(17.1m)(19.2m)(43.3m)(81.0m)

Depreciation and Amortization

29.0k166.0k

Accounts Payable

836.0k2.4m1.3m2.6m

Cash From Operating Activities

(11.2m)(15.9m)(41.2m)(73.5m)
Quarterly
USDQ2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(6.1m)(9.9m)(17.8m)(29.2m)(15.9m)(34.0m)(57.9m)(26.2m)

Depreciation and Amortization

19.0k39.0k87.0k86.0k

Accounts Payable

(636.0k)317.0k(368.0k)1.7m(134.0k)3.0m1.0m1.7m

Cash From Operating Activities

(6.9m)(9.6m)(18.5m)(27.7m)(13.5m)(27.5m)(48.9m)(21.8m)
USDFY, 2016

Financial Leverage

1.4 x
Show all financial metrics

Y-mAbs Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Y-mAbs Therapeutics Online and Social Media Presence

Embed Graph

Y-mAbs Therapeutics News and Updates

Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announc…

Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced toda…

Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference

NEW YORK, March 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced tod…

Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced toda…

Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announ…
Show more

Y-mAbs Therapeutics Blogs

UPDATE - Y-mAbs to Announce First Quarter 2020 Financial and Operating Results on May 7, 2020

NEW YORK , April 30, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020 , after the close of the U.S. financial markets.

Y-mAbs Announces Appointment of Laura J. Hamill to its Board of Directors

NEW YORK , April 24, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. , (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

NEW YORK , April 01, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today

Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments

Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments Content Import Thu, 03/12/2020 - 16:01 Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments Mar 12, 2020 This release is a backfill from a News Wire …

Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

NEW YORK , March 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its 2019 financial and operating results on Thursday, March 12, 2020 , after the close of the U.S. financial markets.

Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

NEW YORK , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced
Show more

Y-mAbs Therapeutics Frequently Asked Questions

  • When was Y-mAbs Therapeutics founded?

    Y-mAbs Therapeutics was founded in 2014.

  • Who are Y-mAbs Therapeutics key executives?

    Y-mAbs Therapeutics's key executives are Thomas Gad.

  • How many employees does Y-mAbs Therapeutics have?

    Y-mAbs Therapeutics has 32 employees.

  • Who are Y-mAbs Therapeutics competitors?

    Competitors of Y-mAbs Therapeutics include Nordic Nanovector, NeuroVive Pharmaceutical and Molecular Partners.

  • Where is Y-mAbs Therapeutics headquarters?

    Y-mAbs Therapeutics headquarters is located at 230 Park Ave #3350, New York.

  • Where are Y-mAbs Therapeutics offices?

    Y-mAbs Therapeutics has offices in New York, Nutley and Hørsholm.

  • How many offices does Y-mAbs Therapeutics have?

    Y-mAbs Therapeutics has 4 offices.